Coronavirus envelope protein is a drug target for new platform for the identification and optimization of peptides against … – EurekAlert

image:

Image Caption: Coauthors Masayuki Yazawa & Lauren Qiu wearing masks at their microscopy room used for this study.

Credit: Image Credit: Masayuki Yazawa (CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)

Coronavirus envelope protein is a drug target for new platform for the identification and optimization of peptides against SARS-CoV-2

#####

In your coverage, please use this URL to provide access to the freely available paper in PLOS Biology: http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002522

Article Title: Developing inhibitory peptides against SARS-CoV-2 envelope protein

Author Countries: United States

Funding: This work was supported by Columbia University Deans Office Fund and Columbia University Translational Therapeutics (TRx) Pilot Award (to M.Y.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Experimental study

Cells

Competing interests: I have read the journals policy and the authors of this manuscript have the following competing interests: M.Y., R.B., K.Y., D.D.H., M.S.N., and Y.H. (inventors) filed a patent (Attorney Docket No.: 01001/00889-US0; status: Filed, 04/13/2022) related to this manuscript. This patent is for using synthetic peptides targeting SARS-CoV-2 envelope protein for treating COVID-19 and related human coronaviruses. The rest of the authors declare no competing interests.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

The rest is here:

Coronavirus envelope protein is a drug target for new platform for the identification and optimization of peptides against ... - EurekAlert